Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Decrease in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 725,979 shares, a decline of 23.1% from the January 29th total of 943,482 shares. Based on an average daily trading volume, of 733,653 shares, the short-interest ratio is presently 1.0 days. Approximately 4.3% of the company’s shares are short sold. Approximately 4.3% of the company’s shares are short sold. Based on an average daily trading volume, of 733,653 shares, the short-interest ratio is presently 1.0 days.

Estrella Immunopharma Stock Down 2.8%

Shares of NASDAQ:ESLA opened at $1.19 on Monday. The business’s 50 day moving average is $1.24 and its 200 day moving average is $1.48. The stock has a market cap of $44.80 million, a P/E ratio of -3.53 and a beta of 0.53. Estrella Immunopharma has a 52-week low of $0.73 and a 52-week high of $3.15.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $8.00 price target on shares of Estrella Immunopharma in a report on Monday, February 9th. Wall Street Zen upgraded Estrella Immunopharma from a “sell” rating to a “hold” rating in a research note on Saturday, January 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Wednesday, January 28th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.00.

Institutional Trading of Estrella Immunopharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new stake in Estrella Immunopharma in the fourth quarter worth about $43,000. State Street Corp increased its position in Estrella Immunopharma by 93.5% during the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after purchasing an additional 20,900 shares during the period. XTX Topco Ltd raised its holdings in shares of Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after purchasing an additional 39,099 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Estrella Immunopharma in the 4th quarter worth approximately $88,000. Finally, Geode Capital Management LLC lifted its position in shares of Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after purchasing an additional 8,318 shares during the period. 0.35% of the stock is currently owned by institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.